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Inclusion criteria 
Studies:  
Randomized and quasi-randomized controlled trials.  
Participants: 
People of any age with sickle cell disease. 
Intervention: 
Intervention: any drug designed to reduce dehydration 
of red blood cells to prevent the blockage of blood 
vessels in sickle cell disease. 
Control: placebo or usual care. 
Outcomes: 
Primary: death, sickle cell pain crisis, other serious 
complications of sickle cell disease. 
Adverse events: any adverse events or drug toxicities. 
Results 
• One trial, involving 145 participants, met the 
inclusion criteria. The trial assessed zinc sulfate 
against a placebo, in participants aged 12 to 27 
years in India. Allocation concealment was not 
reported. 
• No deaths were reported in either group of the 
included trial. 
• The number of sickle cell pain crises appeared to 
be lower in the group taking zinc sulfate (mean 
1.40 compared with 3.38), but the review authors 
did not have access to sufficient data to calculate 
whether the difference was significant.  
• The total number of other serious sickle-related 
complications was significantly lower in the zinc 
sulfate group compared with placebo (weighted 
mean difference -2.83, 95% confidence interval -
3.51 to -2.15). 
• Zinc sulfate was reported to be well tolerated with 
no significant toxicity throughout the study. 
Do drugs that aim to reduce the dehydration of red blood cells 
prevent crises in people with sickle cell disease? 
Zinc sulfate appears promising for preventing sickle cell crises, 
but there is not enough evidence to recommend its use. 
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Authors’ conclusions 
Implications for practice:  
Based on the results of one small trial, zinc sulfate appears promising for reducing the number of pain crises and 
other complications of sickle cell disease.  
Implications for research: 
Further, large multicentre trials are needed to assess the use of zinc sulfate to prevent sickle cell crises, and to 
assess other drugs designed to reduce the dehydration of red blood cells.  
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